Financial Contrast: Strongbridge Biopharma PLC (SBBP) vs. Opiant Pharmaceuticals (OPNT)

Strongbridge Biopharma PLC (NASDAQ: SBBP) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Volatility & Risk

Strongbridge Biopharma PLC has a beta of 2.71, meaning that its share price is 171% more volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals has a beta of -0.94, meaning that its share price is 194% less volatile than the S&P 500.

Insider & Institutional Ownership

62.8% of Strongbridge Biopharma PLC shares are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Strongbridge Biopharma PLC and Opiant Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Strongbridge Biopharma PLC 0 0 3 0 3.00
Opiant Pharmaceuticals 0 0 0 0 N/A

Strongbridge Biopharma PLC currently has a consensus target price of $13.33, suggesting a potential upside of 116.80%. Given Strongbridge Biopharma PLC’s higher possible upside, equities research analysts plainly believe Strongbridge Biopharma PLC is more favorable than Opiant Pharmaceuticals.


This table compares Strongbridge Biopharma PLC and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Strongbridge Biopharma PLC N/A -83.83% -34.77%
Opiant Pharmaceuticals 38.89% 5,686.82% 87.49%

Valuation & Earnings

This table compares Strongbridge Biopharma PLC and Opiant Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Strongbridge Biopharma PLC $1.53 million 142.03 -$39.43 million ($2.78) -2.21
Opiant Pharmaceuticals $14.97 million 4.87 $5.99 million $2.54 14.15

Opiant Pharmaceuticals has higher revenue and earnings than Strongbridge Biopharma PLC. Strongbridge Biopharma PLC is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


Opiant Pharmaceuticals beats Strongbridge Biopharma PLC on 7 of the 12 factors compared between the two stocks.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with's FREE daily email newsletter.

Leave a Reply